Recursion Pharmaceuticals
RXRX
RXRX
312 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 84 funds opening new positions, 114 increasing their positions, 60 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
18% more funds holding
Funds holding: 264 → 312 (+48)
1% less call options, than puts
Call options by funds: $30.7M | Put options by funds: $30.9M
13.51% less ownership
Funds ownership: 92.93% → 79.42% (-14%)
Holders
312
Holding in Top 10
10
Calls
$30.7M
Puts
$30.9M
Top Buyers
| 1 | +$99.2M | |
| 2 | +$68.4M | |
| 3 | +$65.8M | |
| 4 |
BlackRock
New York
|
+$18.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$16.9M |
Top Sellers
| 1 | -$51.8M | |
| 2 | -$8.73M | |
| 3 | -$6.42M | |
| 4 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$5.31M |
| 5 |
NAMA
Nikko Asset Management Americas
New York
|
-$5.31M |